Difficult-to-control Type 2 diabetes (T2D)* may be in the clutches of Hypercortisolism

*CATALYST was a prospective, phase 4 study with two parts. The first part (Screening Phase) assessed the prevalence of endogenous hypercortisolism in 1057 patients with difficult-to-control T2D diagnosed ≥1 year prior and defined as HbA1c 7.5%-11.5% AND taking ≥3 T2D medications OR insulin and other T2D medication(s) OR ≥2 T2D medications AND the presence of ≥1 microvascular or macrovascular complication AND/OR concomitant hypertension requiring ≥2 hypertension medications.  Hypercortisolism was defined as a post 1-mg DST cortisol >1.8 μg/dL with AM dexamethasone ≥140 ng/dL. In the second part (Treatment Phase), patients with hypercortisolism who met inclusion/exclusion criteria (n=136) were randomized (2:1) to receive either Korlym or placebo for 24 weeks in a double-blind, placebo-controlled manner. The primary endpoint was the reduction of HbA1c between these groups. Please see full study design on the CATALYST Study Results page.^1,5